We observed a 3.997 ± 0.676 fold increase in HBG2 expression in baseline SCA patients when compared with normal healthy controls, whereas the expression was further increased to 7.546 ± 2.44 folds after HU therapy. This evidence concerns the gene HBG2 and autosomal dominant cerebellar ataxia.